- CEO
- Akimoto Uchikawa
- Full Time Employees
- 21,834
- Sector
- Industrials
- Industry
- Conglomerates
- Address
- Kasumigaseki Common Gate West Tower Tokyo Japan 100-8585
- IPO Date
- Nov 18, 1996
- Business
- Teijin Limited, a Japanese multinational chemical, pharmaceutical, information technology and materials company (ticker: TINLY), engages in advanced fibers and composites such as aramid fibers including Twaron and Technora, high-performance polyethylene, carbon fibers and reinforced composites under the Tenax brand, flame-resistant fibers, artificial leather and high-performance polyester and PEN fibers; performance polymers including polycarbonate resins, polyphenylene sulfide resins, PET and PEN films and sheets, processed films and high-density polyethylene porous materials; healthcare products encompassing pharmaceuticals for bone and joint, respiratory, cardiovascular, metabolic and other diseases, home healthcare equipment such as oxygen therapy and non-invasive ventilation devices, orthopedic implants, sonic accelerated fracture healing systems, community-based care solutions and functional food ingredients; products converting featuring polyester and recycled polyester fibers and textiles with closed-loop recycling; and IT solutions including RFID inventory management via Recopic, web-based ERP, digital content services, e-commerce and engineering solutions for environmental, energy and workforce challenges. Founded in 1918 and headquartered in Tokyo at Kasumigaseki Common Gate West Tower, the company operates globally across more than 20 countries with 153 group companies, 48 in Japan and 105 overseas, serving industries including automotive, aerospace, electronics, apparel, medical and industrial markets. Recent developments include the March 2025 divestiture of Teijin Automotive Technologies North America to AURELIUS Private Equity, the December 2025 agreement with Asahi Kasei for an absorption-type merger integrating Asahi Kasei Advance into Teijin Frontier to form a joint venture (Teijin 80%, Asahi Kasei 20%) effective October 2026 aimed at enhancing competitiveness in textiles and materials through cross-selling, cost reductions and supply chain integration, and a strategic alliance with BioVaram to expand regenerative medicine and implantable devices targeting JPY 20 billion in sales by fiscal 2030.